Conclusion: Tunicamycin could induce RPMI-8226 cell differentiation for mature stage.
结论：衣霉素可使RPMI- 8226细胞向成熟阶段分化。
This is mainly due to the inhibition of glycosylation of newly synthesized insulin receptor by tunicamycin.
这主要由于衣霉素抑制新合成的胰岛素受体的糖基化所致。
The invention aims at providing a now application of tunicamycin which is the application in preparing a tumour cell reversing drug.
本发明的目的在于提供衣霉素的新的用途，即其在制备肿瘤细胞逆转药物中的应用。
The invention has the advantages of low drug dosage of the tunicamycin, exact effect, less influence on normal cell and benefit for improving the living state of tumour patients.
本发明的优点在于，衣霉素的药物用量低，效果确切，对正常细胞的影响小，有利于改善肿瘤患者的生活状态。
The invention has the advantages of low drug dosage of the tunicamycin, exact effect, less influence on normal cell and benefit for improving the living state of tumour patients.
本发明的优点在于，衣霉素的药物用量低，效果确切，对正常细胞的影响小，有利于改善肿瘤患者的生活状态。
应用推荐